Canada's Gene Bio Medical to build production facility in Binh Dinh

The partnership aims to manufacture high-quality diagnostic test kits using Canadian technology, catering to markets in Vietnam, Southeast Asia, the Middle East, and North America.

The BIDIPHAR-GBM joint venture represents an investment of $10–20 million to develop a state-of-the-art manufacturing facility in Binh Dinh. The collaboration underscores GBM’s commitment to global expansion and pandemic preparedness, positioning the company as a key player in next-generation diagnostics.

Among the joint venture’s key objectives are the advancement of scalable diagnostic solutions for pandemic preparedness and the pursuit of dual listings on the U.S. NASDAQ and Vietnam Stock Exchange within five years.

“Vietnam’s growing healthcare market and strategic location make it an ideal hub for our expansion,” said Jessica Hu, CEO and founder of Gene Bio Medical. “Our partnership with BIDIPHAR will leverage Canadian technology to provide affordable, high-quality diagnostic solutions across global markets. This joint venture aligns with GBM’s mission to enhance global health security through innovation and accessibility.”

GBM, headquartered in British Columbia, Canada, is recognised for its innovations in molecular diagnostics and AI-driven healthcare solutions. The company has an established distribution network across 4,900 independent pharmacies and hospitals in Canada, with its respiratory diagnostic product line expected to receive US Food and Drug Administration approval in 2025.

Binh Dinh has emerged as a premier investment destination in Vietnam, offering a range of incentives for foreign investors, including corporate income tax benefits, import tax exemptions, and land rental incentives.

“We welcome Gene Bio Medical’s investment in Binh Dinh’s biotechnology sector, a key pillar of our economic strategy,” said Lam Hai Giang, Vice Chairman of Binh Dinh People’s Committee. “The province remains committed to supporting international investors by providing world-class infrastructure and regulatory incentives.”

With strong infrastructure and investor-friendly policies, the BIDIPHAR-GBM joint venture is well-positioned for long-term success, contributing to the advancement of Vietnam’s biotechnology sector and expanding its role in the global diagnostics market.

Vietnam aims to develop and apply biotechnology as part of the country's sustainable development, striving to build an international-standard industry.

Kraig Biocraft Laboratories, Inc. (Kraig Labs), the American biotechnology company focused on the development and commercialisation of spider silk, has strengthened its operation in Vietnam to tap into the country’s silk production.

Unlocking the power of health innovation and biotechnology will help Vietnam keep pace with global trends in healthcare research and development, providing a golden opportunity for healthcare and pharmaceutical startups to rise and thrive.